Di Yi Cai Jing Zi Xun·2025-09-30 16:23Group 1 - Merck and GSK have announced leadership changes, with both companies appointing internal successors to their female CEOs, reflecting increasing challenges faced by multinational corporations [2] - GSK appointed Luke Miels as the new CEO, effective January 1, 2024, succeeding Emma Walmsley, who has served for nine years and oversaw an 11% decline in stock price during her tenure [4] - GSK's leadership changes come amid concerns about its ability to achieve a sales target of over £40 billion by 2031, compounded by challenges in the vaccine market and recent executive departures [4][5] Group 2 - Merck announced that Kai Beckman will take over as CEO from Belén Garijo on May 1, 2026, with Garijo remaining in her role in the healthcare division [5] - Under Garijo's leadership, Merck has pursued a differentiated strategy focusing on medium-sized transactions rather than large acquisitions, with a target deal value of €500 million to €600 million [6] - Garijo highlighted the need for supply chain adjustments and strategic flexibility to navigate global trade uncertainties and the complexities of the Chinese healthcare market [6]